(Washington) The United States Medicines Agency on Wednesday authorized Novavax’s COVID-19 vaccine for adults 18 and older, providing an additional option for getting vaccinated in the United States, in hopes of help convince the reluctant.
Posted at 5:37 p.m.
The vaccine produced by this American company is already available in dozens of other countries.
In the United States, on the other hand, only three anti-COVID-19 vaccines were currently authorized: those with messenger RNA from Pfizer and Moderna, and that from Johnson & Johnson. But access to the latter has been limited due to an increased risk of serious thrombosis.
The emergency authorization of the Novavax vaccine will “offer American adults who have not yet received a vaccine against COVID-19 another option”, welcomed in a press release Robert Califf, the head of the agency of the drugs (FDA).
Administered in two doses three weeks apart, it uses a more traditional technique than messenger RNA, which has been the target of many conspiracy theories, although it has been shown to be very safe.
The Novavax vaccine contains a component of the virus that triggers an immune response, similar to the pertussis, meningococcal meningitis and hepatitis B vaccines.
In clinical trials, conducted on several thousand people in the United States and Mexico, it was found to be 90% effective against symptomatic cases of COVID-19. A figure which must however be put into perspective, these tests having been conducted before the Delta and Omicron variants.
“Americans can be confident that this vaccine, like all other vaccines used in the United States, has undergone the rigorous and comprehensive scientific review of the FDA,” said Peter Marks, senior official at the ‘agency.
The vaccination rate for the adult population is stagnating around 77% in the United States.
The US government announced this week that it had purchased 3.2 million doses of the vaccine from Novavax, anticipating the FDA’s decision.